Meitav Dash Investments Ltd. Lowers Position in iShares Biotechnology ETF (NASDAQ:IBB)

Meitav Dash Investments Ltd. lessened its stake in iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 0.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,720 shares of the financial services provider’s stock after selling 218 shares during the period. Meitav Dash Investments Ltd.’s holdings in iShares Biotechnology ETF were worth $4,002,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Wealthsource Partners LLC boosted its position in iShares Biotechnology ETF by 18.3% in the 1st quarter. Wealthsource Partners LLC now owns 3,522 shares of the financial services provider’s stock worth $459,000 after purchasing an additional 546 shares in the last quarter. ICICI Prudential Asset Management Co Ltd purchased a new position in shares of iShares Biotechnology ETF during the 1st quarter valued at approximately $995,000. Lincoln National Corp lifted its position in shares of iShares Biotechnology ETF by 15.0% during the 1st quarter. Lincoln National Corp now owns 8,247 shares of the financial services provider’s stock valued at $1,075,000 after buying an additional 1,075 shares in the last quarter. Tredje AP fonden purchased a new position in shares of iShares Biotechnology ETF during the 1st quarter valued at approximately $9,121,000. Finally, Proffitt & Goodson Inc. lifted its position in shares of iShares Biotechnology ETF by 3.3% during the 1st quarter. Proffitt & Goodson Inc. now owns 6,785 shares of the financial services provider’s stock valued at $884,000 after buying an additional 215 shares in the last quarter. Hedge funds and other institutional investors own 63.88% of the company’s stock.

iShares Biotechnology ETF Trading Up 1.0 %

Shares of NASDAQ:IBB opened at $131.44 on Friday. iShares Biotechnology ETF has a 1 year low of $104.29 and a 1 year high of $177.37. The business’s 50 day moving average price is $119.28 and its 200-day moving average price is $122.98.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 15th. Stockholders of record on Friday, June 10th were paid a $0.031 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.09%. The ex-dividend date of this dividend was Thursday, June 9th.

About iShares Biotechnology ETF

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.